Download PDF
Endo-Praxis 2025; 41(02): 75-83
DOI: 10.1055/a-2541-7356
Weiterbildung

Präventionsstrategien gastrointestinaler Tumoren

Michael Quante
,
Susann Schütte
› Further Information
Also available at
   Permissions and Reprints

Innerhalb der letzten Jahrzehnte konnten in der (frühzeitigen) Diagnostik und Therapie sowie in der Primär-, Sekundär- und Tertiärprävention gastrointestinaler onkologischer Erkrankungen maßgebliche Fortschritte verzeichnet werden. Im Folgenden werden aktuelle Erkenntnisse und Empfehlungen in der Prävention von gastrointestinalen Tumoren zur Integration in den klinischen Praxisalltag zusammengefasst.



Publication History

Article published online:
27 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Hoffmeister M, Holleczek B, Zwink N. et al. Screening for bowel cancer: Increasing participation via personal invitation. Dtsch Arztebl Int 2017; 114: 87-93
    CrossrefPubMedSearch in Google Scholar
  • 2 Marabotto E, Pellegatta G, Sheijani AD. et al. Prevention strategies for esophageal cancer – an expert review. Cancers 2021; 13: 2183
    CrossrefPubMedSearch in Google Scholar
  • 3 Teufel A, Quante M, Kandulski A. et al. Prävention gastrointestinaler Tumore. Z Gastroenterol 2021; 59: 964-982
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol 2021; 18: 432-443
    CrossrefPubMedSearch in Google Scholar
  • 5 Norwood DA, Montalvan-Sanchez E, Dominguez RL. et al. Gastric cancer: Emerging trends in prevention, diagnosis, and treatment. Gastroenterol Clin North Am 2022; 51: 501-518
    CrossrefPubMedSearch in Google Scholar
  • 6 Wani S, Falk GW, Post J. et al. Risk factors for progression of lowgrade dysplasia in patients with Barrett’s esophagus. Gastroenterology 2011; 141: 1179-1186 1186.e1
    CrossrefPubMedSearch in Google Scholar
  • 7 Hvid-Jensen F, Pedersen L, Drewes AM. et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-1383
    CrossrefPubMedSearch in Google Scholar
  • 8 Fitzgerald RC, di Pietro M, O’Donovan M. et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet 2020; 396: 333-344
    CrossrefPubMedSearch in Google Scholar
  • 9 Li D, Jiang SF, Lei NY. et al. Effect of Helicobacter pylori eradication therapy on the incidence of noncardia gastric adenocarcinoma in a large diverse population in the United States. Gastroenterology 2023; 165: 391-401.e2
    CrossrefPubMedSearch in Google Scholar
  • 10 Leitlinienprogramm Onkologie. S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome. AWMF-Registernummer: 032-053OL. Langversion 4.0. August 2023. Zugriff am 20.11.2023 unter https://register.awmf.org/de/leitlinien/detail/032-053OL
  • 11 Simon TG, Duberg AS, Aleman S. et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med 2020; 382: 1018-1028
    CrossrefPubMedSearch in Google Scholar
  • 12 Behrens G, Jochem C, Schmid D. et al. Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis. Eur J Epidemiol 2015; 30: 279-298
    CrossrefPubMedSearch in Google Scholar
  • 13 Villard C, Friis-Liby I, Rorsman F. et al. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol 2023; 78: 604-613
    CrossrefPubMedSearch in Google Scholar
  • 14 Quante AS, Ming C, Rottmann M. et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med 2016; 5: 2649-2656
    CrossrefPubMedSearch in Google Scholar
  • 15 Raimondi S, Lowenfels AB, Morselli-Labate AM. et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24: 349-358
    CrossrefPubMedSearch in Google Scholar
  • 16 Lal G, Liu G, Schmocker B. et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germline p16, BRCA1, and BRCA2 mutations. Cancer Res 2000; 60: 409-416
    PubMedSearch in Google Scholar
  • 17 Seufferlein T, Porzner M, Becker T. et al. S3-guideline exocrine pancreatic cancer. Z Gastroenterol 2013; 51: 1395-1440
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Canto MI, Almario JA, Schulick RD. et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 2018; 155: 740-751.e2
    CrossrefPubMedSearch in Google Scholar
  • 19 Barnes B, Kraywinkel K, Nowossadeck E. Robert Koch-Institut et al. Bericht zum Krebsgeschehen in Deutschland 2016. Berlin: Robert Koch-Institut; 2016. Zugriff am 20.11.2023 unter https://edoc.rki.de/handle/176904/3264
    Search in Google Scholar
  • 20 Labianca R, Nordlinger B, Beretta GD. et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi64-vi72
    CrossrefPubMedSearch in Google Scholar
  • 21 Riemann JF, Schilling D, Hüppe D. et al. Das neue Darmkrebs-Screening. Z Gastroenterol 2020; 58: 787-788
    Thieme ConnectSearch in Google Scholar
  • 22 Leitlinienprogramm Onkologie. S3-Leitlinie Kolorektales Karzinom. AWMF-Registernummer: 021/007OL. Langversion 2.1. Januar 2019. Zugriff am 20.11.2023 unter https://register.awmf.org/de/leitlinien/detail/021-007OL